

QUANTITY LIMIT CRITERIA

DRUG CLASS	DRONABINOL PRODUCTS
BRAND NAME (generic)	MARINOL (dronabinol)
	SYNDROS (dronabinol oral solution)
Status: CVS Caremark Criteria	
Type: Quantity Limit	

POLICY

FDA-APPROVED INDICATIONS

Marinol and Syndros are indicated for the treatment of:

- anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS).
- nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

REFERENCES

1. Marinol [package insert]. North Chicago, IL: AbbVie Inc.; December 2018.
2. Syndros [package insert]. Chandler, AZ: Insys Therapeutics, Inc.; September 2018.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed January 2019.
4. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed January 2019.
5. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemesis. V.3.2018. Available at: www.nccn.org . Accessed January 2019.

LIMIT CRITERIA

Limits should accumulate across all drugs and strengths up to highest quantity listed depending on the order the claims are processed. Accumulation does not apply if limit is coded for daily dose.

Drug	1 Month Limit*	3 Month Limit*
Marinol 2.5 mg, 5 mg, 10 mg capsules	60 capsules /25 days	180 capsules /75 days
Syndros oral solution	120 mL/25 days	360 mL/75 days

*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.